ProQR Therapeutics N.V. received a Buy rating due to promising phase 1 results for its AX-0810 drug, which showed an 8-fold increase in serum bile acids, surpassing targets and indicating potential to treat biliary atresia. Key upcoming events include full phase 1 data for AX-0810 by end-2026, pediatric data from China in early 2027, and phase 1 results for next-gen AX-0811 by end-2026. With solid cash reserves and a partnership with Eli Lilly, ProQR is positioned for significant value growth through mid-2028.
A large holder transferred 541,000 Hyperliquid (HYPE) tokens worth about $49.5 million to the Kraken exchange, suggesting a potential gain of $9.52 million based on previous purchase prices. The tokens were originally withdrawn from Coinbase Prime at...
Corteva announced that the SEC has approved Vylor's registration, enabling Vylor to become an independent publicly traded company on October 1, 2026. Corteva shareholders as of September 24, 2026, will receive one share of Vylor for each Corteva shar...
XRP's 365-day Market Value to Realized Value (MVRV) ratio stood at about -11.75% on September 23, indicating that XRP coins active in the past year are valued below their average acquisition cost, reflecting unrealized losses. This metric measures pr...
XRP's average unrealized return for coins active in the past year remains negative at minus 11.75%, according to Santiment. Despite a recent price surge above $1.60 and increased transaction activity, the average long-term trader has not returned to ...
Cardinal Infrastructure Group reported a drop in its second quarter 2026 gross profit margin to 10.8%, down from 13.9% in the same quarter last year, due to higher subcontracted labor and equipment rental costs. This shift reflects a strategic move t...
